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Abstract
The surfactant components saturated phosphatidylcholine, SP-B and SP-C, are secreted together in lamellar bodies, and at
least a part of the de novo synthesized SP-A is secreted independently. The surface film forms from tubular myelin and loose
lipid arrays, and it generates unilamellar vesicles that lack surfactant proteins and are thought to represent catabolic forms.
The half-life values for the clearance of surfactant proteins from lungs range from 6.5 to 28 h and vary with species. There is
minimal information about the associations of the surfactant proteins with lipids or with each other after film formation,
although all surfactant components seem to be recycled back into lamellar bodies in type II cells. The relative importance of
type II cells or macrophages to the catabolism of the protein components of surfactant remains to be characterized, as do
regulators of surfactant homeostasis. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
This brief review will focus on the alveolar metab-
olism of the surfactant proteins and their clearance
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kinetics from the lungs. Although the overall scheme
for the metabolism of the surfactant lipids once se-
cretion to the alveolus has occurred is relatively well
known, the forms assumed by and metabolic path-
ways taken by the surfactant proteins remain enig-
matic [1,2]. A general scheme for the alveolar metab-
olism of the lipid and protein components is outlined
in Fig. 1. Because the saturated phosphatidylcholines
are essential for ¢lm formation and contribute the
largest mass to surfactant, the metabolic pathways
of these lipids are basic to exploring how the surfac-
tant proteins £ow from secretion to alveolar clear-
ance and ultimately catabolism. Phosphatidylcho-
lines destined to surfactant are synthesized as
saturated phosphatidylcholine (Sat PC) species and
unsaturated species that are transacylated to satu-
rated species before integration into lipid latices in
lamellar bodies. The lamellar bodies have the same
lipid composition of alveolar forms taken by surfac-
tant. Once lamellar bodies are exocytosed from type
II cells, the lamellar bodies ‘unravel’ spontaneously
in the hypophase to form tubular myelin and loose
lipid arrays (multivesicular liposomes, large aggre-
gate forms, heavy surfactant) [3]. The tubular myelin
and loose lipid arrays provide the lipids which ad-
sorb to the air-£uid interface to form the surface
¢lm. With surface area expansion and compression,
small unilamellar vesicles (small aggregates, light
forms) are generated which re-enter the hypophase.
These vesicles that have poor surface active proper-
ties are thought to be the catabolic forms for the
surfactant lipids [4].
The alveolar forms assumed by the lipid and pro-
tein components of surfactant were ¢rst separated
and characterized in 1983 in Dr. Clements’ labora-
tory [5]. Subsequently Wright et al. [6] demonstrated
that the small vesicles contained no SP-A. Baritussio
et al. [7] and Gross and Narine [8] used density gra-
dient separations to demonstrate that the small
vesicles were products of tubular myelin and loose
lipid arrays by measuring the time of appearance of
radiolabeled Sat PC into the di¡erent forms of sur-
factant. Baritussio et al. [4] and Putman et al. [9]
found no SP-B or SP-C associated with the small
vesicles that comprise about 50% of the Sat PC in
the alveolar pool.
The Sat PC in the airspace is taken up and ca-
tabolized by macrophages or is taken up by type II
cells to be catabolized or recycled back into lamellar
bodies for resecretion. In the rabbit, about 10^20%
of the Sat PC is catabolized by macrophages and
50% is recycled with the residual being catabolized
by type II cells [10]. These estimates were based on
measurements made with the phospholipase-A2 re-
sistant diether analog of dipalmitoylphosphatidyl-
choline. Sat PC, analogs of Sat PC, and other phos-
pholipids are taken up from the airspace with similar
kinetics and are recycled without being broken down
into precursors and resynthesized to a large extent
[11]. The characteristics of the overall metabolism
of Sat PC are that alveolar clearance curves are
best ¢t by multicomponent experimental curves be-
cause of the recycling behavior of the Sat PC [12].
Biological half-life values of Sat PC and other
phosphatidylcholine species were ¢rst measured by
Tierney, Clements and Trahan [13] in 1967, and sub-
sequent estimates from many laboratories range from
8 to 12 h in mice, rats and rabbits [1]. The turnover
time for alveolar Sat PC is shorter than the biolog-
ical half-life because, as ¢rst reported by Hallman et
al. [14], surfactant lipids are recycled. The ¢rst esti-
mate of a turnover time was also reported by the
Clements group in 1981 [15], and subsequent esti-
mates in mice, rats, and rabbits are on the order of
5 h, demonstrating the very dynamic metabolism of
surfactant phospholipids [1]. Very little intact Sat PC
is lost from the lungs; therefore, losses of radiola-
beled Sat PC represent catabolism of Sat PC within
the lungs. The metabolism of Sat PC is similar in
terms of pathways and kinetic variables in all ani-
mals studied to date.
The metabolism of Sat PC in the developing lung
is quite di¡erent than metabolism in the adult lung
[16]. The time delay from synthesis to storage in
lamellar bodies and subsequent secretion is much
slower in the late fetal and term newborn lung than
in the adult lung. Lamellar body and alveolar Sat PC
pool sizes are 5^10-fold higher in the term newborn
than in the adult of the same species. The e⁄ciency
of recycling in newborn rabbits is about 90%, and
very little catabolism of Sat PC occurs. For example
the biological half-life of Sat PC in the term newborn
lamb is about 6 days. The explanations for more
recycling and less catabolism are not known but
probably include fewer macrophages in the newborn
lung, di¡erences in catabolic and recycling activities
BBADIS 61773 30-10-98
M. Ikegami, A.H. Jobe / Biochimica et Biophysica Acta 1408 (1998) 218^225 219
by type II cells, and di¡erences in receptors for other
surfactant components that may in£uence Sat PC
uptake.
2. SP-A
The general pathways taken from synthesis to ca-
tabolism of SP-A are known, although the relative
importance of di¡erent lung cell types are not known
[2]. De novo synthesized SP-A is rapidly secreted to
the airspace in preterm lambs and adult rabbits be-
fore signi¢cant radiolabeling of lamellar bodies by de
novo synthesized SP-A [17,18] (Fig. 2). Therefore,
some of the new SP-A is (constitutively?) secreted
to the alveolar space by a pathway that is separate
from the processing and storage of other surfactant
components. Some de novo synthesized SP-A could
be co-processed with the other surfactant compo-
nents and end up in lamellar bodies. However, there
is another pathway that can explain the lower SP-A
content of lamellar bodies than tubular myelin and
loose lipid arrays [19]. As demonstrated by electron
microscopy using immunologic techniques and with
radiolabel, SP-A is taken up by type II cells and
recycled via multivesicular bodies into lamellar
bodies [20]. Subcellular fraction techniques also dem-
onstrate concentration of radiolabeled SP-A in la-
mellar bodies after intratracheal administration [21].
Further complicating SP-A metabolism in vivo,
Clara cells contain mRNA for SP-A and mature
SP-A in the secretory granules, although secretion
of SP-A by Clara cells has not been demonstrated.
The de novo synthesized SP-A that is initially se-
creted by newborn rabbits has a molecular mass of
26 kDa, and glycosylated forms of higher molecular
weight predominate at later times (Fig. 3). Therefore,
the following questions remain to be answered. (1)
What is the contribution of Clara cells to SP-A me-
tabolism? (2) Is the de novo synthesized SP-A that
enters the airspaces secreted from type II cells, Clara
cells or both cell types? (3) Does de novo synthesized
SP-A enter lamellar bodies only via the recycling
pathway? (4) Why are low molecular weight forms
initially found in the airspaces?
Once secreted to the airspaces, SP-A is cleared
somewhat more rapidly than is Sat PC, and SP-A
appears in lamellar body fractions with kinetics sim-
ilar to Sat PC, although less e⁄ciently [21]. This low-
Fig. 1. General scheme for the movement of the lipid and pro-
tein components of surfactant from secretion to reuptake and
catabolism.
Fig. 2. Labeling of SP-A in adult rabbits and preterm lambs.
Rabbits were given [3H]methionine by intratracheal injection
and [3H]SP-A appeared in the alveolar washes before labeling
was detected in lamellar bodies. For the preterm lamb studies,
ventilated lambs at 138 days gestation were given
[35S]methionine via the trachea shortly after birth and [35S]SP-A
was measured in alveolar washes. In separate experiments the
appearance of de novo synthesized Sat PC was measured. The
curves for SP-A and Sat PC are very di¡erent. Data redrawn
from [17,18].
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er recovery of SP-A than Sat PC in lamellar bodies
indicates less e⁄cient recycling of SP-A than Sat PC.
SP-A and degradation products are also recovered
with macrophages. The half-life for loss of radiola-
beled SP-A from the lungs of adult rabbits is 6.5 h in
comparison to 12 h for Sat PC [21] (Fig. 4). In the
adult mouse, radiolabeled SP-A is lost with a half-life
of 6 h in comparison to 8 h for Sat PC. Therefore,
SP-A is somewhat more rapidly cleared than is Sat
PC. The relative contributions of type II cells or
macrophages to catabolism are not known.
There is less information about the metabolism of
SP-A than Sat PC in the developing lung. SP-A
mRNA levels are low until just prior to delivery,
and radiolabeled SP-A is cleared from the airspaces
of near term lambs more rapidly than is Sat PC [17].
The kinetics of labeling, secretion, and persistence of
radiolabeled SP-A in the airspaces of newborn rab-
bits indicates that, as with Sat PC, SP-A is cleared
from the developing lung more slowly than from the
adult lung [18]. However, measurements of SP-A
clearance and catabolism have not been made in
the developing lung.
Based on extensive information derived from in
vitro experiments SP-A was thought to be an impor-
tant regulator of the alveolar metabolism of other
surfactant components [2]. SP-A inhibits surfactant
secretion and stimulates Sat PC uptake by type II
cells, presumably via several classes of receptors
identi¢ed on both type II cells and macrophages.
However, transgenic mice that are de¢cient in SP-A
have surfactant pool sizes and phospholipid compo-
sitions similar to wild type mice [22], and measure-
ments of metabolism for Sat PC and SP-B were sim-
ilar for SP-A de¢cient and wild type mice [23].
Unless there are compensatory mechanisms, SP-A
is not an important regulator of surfactant metabo-
lism in vivo under steady state conditions. A possible
explanation for the inconsistencies between the in
vivo results and the metabolic e¡ects demonstrated
in vitro is the concentration of surfactant. In the
alveolus, surfactant is probably at concentrations of
about 10 mg/ml while in vitro studies have utilized
much lower concentrations. SP-A aggregates lipids
and accumulates on cell surfaces, making observa-
tions prone to artifact. Isolated type II cells and
macrophages may respond to low concentrations of
SP-A and lipids di¡erently in vitro than when bathed
in very high concentrations in vivo. The results with
SP-A de¢cient mice have challenged many concepts
about the metabolic functions of SP-A [22]. Trans-
genic mice with abnormalities in surfactant metabo-
lism should facilitate studies to explore the complex-
ities of surfactant metabolism.
3. SP-B
The mature lipophilic SP-B is localized only to
lamellar bodies in type II cells, and inactivation of
the SP-B gene results in disruption of lamellar bodies
and normal processing of other surfactant compo-
nents [24]. However, SP-B de¢ciency does not alter
precursor incorporation into Sat PC in the fetal
mouse lung at term, indicating that a disruption of
Fig. 4. Clearance curves for surfactant components from the
lungs of adult rabbits. Data from [21,27,37].
Fig. 3. Molecular mass of de novo synthesized SP-A in the air-
spaces of 3 day old rabbits. Rabbits were given 35S labeled me-
thionine and cysteine (Tran-35S, ICN Biochemicals, Costa
Mesa, CA) by tracheal injection and the ratio of radiolabeled
[36S]SP-A with a molecular mass of 26 kDa to total radiola-
beled SP-A was measured. The majority of the [35S]SP-A ini-
tially recovered by alveolar washes soon after the precursor ad-
ministration had a molecular mass of about 26 kDa.
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surfactant packaging and secretion does not interfere
with Sat PC synthesis [25]. However, once SP-B and
Sat PC are in lamellar bodies, they have secretion
kinetics that are parallel [26]. Baritussio et al. [4]
demonstrated that SP-B was taken up by type II cells
and recycled into lamellar bodies in newborn rabbits.
In more complete studies using adult rabbits Ueda et
al. [27] found that radiolabeled SP-B was cleared
from the airspaces and lost from lamellar bodies
more rapidly than was Sat PC, results consistent
with SP-B being recycled less e⁄ciently than Sat
PC. SP-B was found in macrophages, indicating a
potential role for macrophages in the catabolism of
SP-B. The biological half-life of 7 h for SP-B was
shorter than the 10^12 h measured for Sat PC (Fig.
4). In contrast to the rabbit, the alveolar clearance of
SP-B (half-life=28 h) was slower than was the clear-
ance of Sat PC (half-life of 8^11 h) in the mouse [23].
The basis for this species di¡erence in SP-B catabo-
lism is not known.
SP-B and SP-A are essential for tubular myelin
formation, and SP-B is thought to be critical for
¢lm formation [28]. Antibodies to SP-B disrupt sur-
factant function in vivo [29], SP-B de¢ciency results
in lethal respiratory failure at birth [24], and surfac-
tants containing only SP-B and lipids are very e¡ec-
tive for the treatment of surfactant de¢cient animals
[30]. However, surfactants that contain only SP-C
can be equally e¡ective [31]. The essential require-
ment for SP-B for surfactant function has not been
de¢nitively demonstrated because animals that lack
SP-B also have incompletely processed SP-C and an
absence of normal surfactant storage and secretion
pathways [25]. Antibodies to SP-B could inactivate
surfactant by mechanisms independent of interfer-
ence with the biophysical properties of SP-B.
The enigma about SP-B is how this lipophilic pro-
tein moves from secretion to clearance and catabo-
lism. Once SP-B is in the airspace, its fate is largely
unknown. Baritussio et al. [4] tentatively identi¢ed an
SP-B rich fraction that did not contain very much
lipid on continuous equilibrium sucrose density gra-
dients at densities higher than large aggregate surfac-
tant. The characteristics of these SP-B rich ‘rem-
nants’ are unknown. Questions are: with which
other surfactant components SP-B may be associat-
ing, if the SP-B is denatured, and if there are forms
of SP-B destined for recycling and/or catabolism. A
surprising ¢nding is that the unilamellar vesicles con-
taining approx. 50% of surfactant lipids in the alveoli
have no detectable SP-B [9]. How the lipids separate
from the proteins is not known. Presumably SP-B
must enter fractions with some lipid because of its
hydrophobic nature. Based on in vitro measurements
using the surface area cycling techniques of Gross et
al. [32], the change in surfactant from large aggregate
to small vesicular forms that lack SP-B requires a
carboxylesterase. The substrate for this ‘convertase’
has not been identi¢ed. As with the other surfactant
components measured to date, the lung clearance of
SP-B is very slow in the term newborn and preterm
[26,33]. Although the overall kinetics of SP-B has
been described, details of its behavior in the airspace
remain to be characterized.
4. SP-C
This extremely hydrophobic protein is found fully
processed only in lamellar bodies and presumably is
secreted concurrently with Sat PC and SP-B,
although coordinated secretion has not been meas-
ured in vivo. Part of the reason for a lack of infor-
mation about the metabolism of SP-C results from
the di⁄culty in purifying the protein, its tendency to
self-aggregate and denature, and the lack of a reli-
able assay [34]. As with SP-B and the other surfac-
tant components, radiolabeled SP-C given via the
airways will leave the alveolar surfactant and become
associated with lamellar bodies, a behavior consistent
with recycling. The small vesicular forms of surfac-
tant also lack SP-C [9]. Short term studies by Pinto
et al. [35] in adult rats suggest that the associations
of SP-C and Sat PC with lamellar bodies occur at
similar rates after intratracheal administration of the
radiolabeled surfactant components. Baritussio et al.
[36] reported that SP-C may be turned over more
rapidly than Sat PC in newborn rabbits. We recently
found similar alveolar clearance curves for Sat PC,
native SP-C, and a recombinant SP-C (rSP-C) with
phenylalanine replacing cysteine in positions 4 and
5 and isoleucine replacing methionine in position
32 of the human sequence in rabbits [37]. The half-
life values for native and recombinant SP-C clearan-
ces from the lungs were about 11 h. Very little native
SP-C or rSP-C was recovered in the macrophages. In
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mice the rSP-C was cleared with a half-life of 27 h,
which was signi¢cantly longer than the half-life of
12 h measured for Sat PC in the same animals [37].
As with SP-B, this lipophilic protein is lost more
slowly from mouse lungs than rabbit lungs. Because
there is no information about catabolic pathways of
SP-C, the reasons for the di¡erence are not known.
The forms taken or mechanisms of clearance of
SP-C from the airspace after ¢lm formation remain
unde¢ned. As with SP-B, Baritussio et al. [4] found
that SP-C was sedimented as particulate material on
continuous equilibrium sucrose gradients and was
not contained in the small vesicle fraction. The mech-
anism by which the small vesicles that lack SP-C are
generated from the surface ¢lm is unde¢ned, as is the
nature of the SP-C after it leaves large aggregate
surfactant. An interesting hypothesis is that depalmi-
toylation of SP-C might occur during form conver-
sion in the airspace. An inconsistency is the observa-
tion that liposomes containing SP-C are taken up
preferentially by type II cells relative to lipid only
liposomes or liposomes that contain SP-A or SP-B
[38], but the catabolic small vesicles recovered by
alveolar wash do not contain SP-C [9].
5. Regulation of surfactant pools in vivo
Mechanisms regulating steady state alveolar pool
sizes are not known. Acute changes in alveolar pools
can be induced by exercise, stretch and secreta-
gogues, and more chronic changes can result from
glucocorticoids, silica dust, or radiation injury for
example [1]. Recent serendipitous observations with
transgenic mice demonstrate that cytokines can reg-
ulate surfactant homeostasis. Mice that overexpress
IL-4 in Clara cells have increased alveolar pools of
surfactant proteins [39]. Mice that are de¢cient in
granulocyte-macrophage colony-stimulating factor
(GM-CSF) have an alveolar proteinosis syndrome
characterized by a 10-fold or greater increase in sur-
factant components, normal precursor incorporation
Fig. 5. Metabolic measurements for control mice (GM+), mice that lack GM-CSF (GM3), and mice that express GM-CSF from a
human SP-C promoter GM-CSF construct only in airway epithelial cells (GMtg+). Incorporation of radiolabeled palmitic acid was
measured at 3 h, and percent secretion was calculated as radiolabeled Sat PC in alveolar wash divided by total radiolabeled Sat PC in
the lungs U100. Recoveries of radiolabeled Sat PC, SP-A, and SP-B were measured in mice 40 h after intratracheal injection. GM-
CSF has large e¡ects on surfactant lipid and protein metabolism. Data from [40,41].
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into Sat PC and secretion but very slow catabolism
of Sat PC, SP-A and SP-B (Fig. 5) [40,41]. This ab-
normality does not alter the appearance of type II
cells, but macrophages become foamy. Replacement
of GM-CSF using the SP-C promoter to express
GM-CSF only in airway epithelial cells corrects the
alveolar pool size of Sat PC but the numbers of type
II cells and macrophages increase, probably because
local expression of GM-CSF acts as a growth factor.
The precise e¡ects of GM-CSF on surfactant com-
ponent clearance and catabolism by macrophages
and type II cells remains to be de¢ned. However,
GM-CSF de¢ciency clearly demonstrates that cyto-
kines can regulate surfactant metabolic pathways.
6. Unresolved issues
The overall kinetics of alveolar and lung clearance
for the surfactant proteins SP-A, SP-B and SP-C
have been measured. However, very little is known
about the pathways, forms and associations taken by
the surfactant proteins in the airspace. There is no
information about metabolic variables for SP-D. The
surprises from studies of surfactant metabolism and
function in SP-A de¢cient mice suggest considerable
caution in the extrapolation of in vitro results to in
vivo. The integrated regulation of surfactant homeo-
stasis is not understood, although results from stud-
ies with mice de¢cient in GM-CSF demonstrate that
regulators of the metabolic pathways of surfactant
exist. Their identities and mechanisms of action re-
main to be de¢ned. The catabolic pathways and cells
responsible for the majority of the catabolism of the
surfactant proteins also remain to be identi¢ed.
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